Keros Therapeutics Cuts Workforce by 50% and Halts Cardiovascular Drug Development

Keros Therapeutics has announced significant layoffs, reducing its workforce by nearly 50%. The company also confirmed it will halt development of its cardiovascular disease drug. This decision comes as part of a broader strategic shift within the organization. Meanwhile, Astellas Pharma has entered into an agreement to invest in a Chinese biotechnology firm specializing in antibody-drug conjugates (ADCs), signaling continued interest in the growing field of targeted cancer therapies.

In other developments within the biotech sector, Stealth Biotherapeutics and Taysha Gene Therapies have each reported progress toward potential FDA approval for their respective treatments. Both companies claim to have identified viable regulatory pathways that could bring their therapies closer to market. These announcements reflect ongoing activity and adjustments across the pharmaceutical and biotech industries as companies navigate evolving priorities and opportunities.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 30, 2025

Author

Mark Chiang